Boston Scientific Corporation Website

Boston Scientific Corporation

NYSE-BSX

Basic

  • Market Cap

    $109.18B

  • EV

    $118.09B

  • Shares Out

    1,470.18M

  • Revenue

    $15.23B

  • Employees

    48,000

Margins

  • Gross

    68.79%

  • EBITDA

    25.98%

  • Operating

    17.96%

  • Pre-Tax

    14.06%

  • Net

    12%

  • FCF

    12.58%

Returns (5Yr Avg)

  • ROA

    5.48%

  • ROTA

    27.97%

  • ROE

    11.66%

  • ROCE

    6.89%

  • ROIC

    -1.84%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $86.88

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $2,329M

  • Net Debt

    $8,672M

  • Debt/Equity

    0.55

  • EBIT/Interest

    9.91

Growth (CAGR)

  • Rev 3Yr

    10.8%

  • Rev 5Yr

    8.61%

  • Rev 10Yr

    7.86%

  • Dil EPS 3Yr

    49.24%

  • Dil EPS 5Yr

    4.39%

  • Dil EPS 10Yr

    21.12%

  • Rev Fwd 2Yr

    11.2%

  • EBITDA Fwd 2Yr

    13.82%

  • EPS Fwd 2Yr

    13.79%

  • EPS LT Growth Est

    12.08%

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

10,735

9,913

11,888

12,682

14,240

15,229

Total Revenues % Chg.

9.3%

-7.7%

19.9%

6.7%

12.3%

13.6%

Cost of Goods Sold, Total

3,103

3,242

3,760

4,003

4,391

4,753

Gross Profit

7,632

6,671

8,128

8,679

9,849

10,476

Selling General & Admin Expenses, Total

3,928

3,787

4,359

4,520

5,190

5,430

R&D Expenses

1,174

1,143

1,204

1,323

1,414

1,468

Amortization of Goodwill and Intangible Assets

699

789

741

803

828

843

Other Operating Expenses, Total

5,801

5,719

6,304

6,646

7,432

7,741

Operating Income

1,831

952

1,824

2,033

2,417

2,735

Interest Expense, Total

-473

-361

-341

-470

-265

-276

Interest And Investment Income

30

3

4

10

22

22

Net Interest Expenses

-443

-358

-337

-460

-243

-254

Currency Exchange Gains (Loss)

-35

-32

-27

-31

-41

-41

Other Non Operating Income (Expenses)

1

6

-7

-14

-16

29

EBT, Excl. Unusual Items

1,354

568

1,453

1,528

2,117

2,469

Restructuring Charges

-83

-179

-40

-24

-69

-58

Merger & Related Restructuring Charges

-369

—

—

—

—

-1

Impairment of Goodwill

—

—

—

—

—

—

-73

—

—

—

—

Gain (Loss) On Sale Of Investments

-30

383

250

-1

-59

-58

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

78

-22

—

—

Asset Writedown

-105

-452

-370

-132

-58

-277

Legal Settlements

-115

-278

-430

-173

111

111

Other Unusual Items

35

-49

136

-35

-58

-45

EBT, Incl. Unusual Items

687

-80

1,077

1,141

1,984

2,141

Income Tax Expense

-4,013

2

36

443

393

319

Earnings From Continuing Operations

4,700

-82

1,041

698

1,591

1,822

Minority Interest

—

—

—

—

—

—

—

—

—

1

5

Net Income

4,700

-82

1,041

698

1,592

1,827

Preferred Dividend and Other Adjustments

—

—

—

—

—

—

33

56

56

22

-1

Net Income to Common Incl Extra Items

4,700

-115

985

642

1,570

1,828

Net Income to Common Excl. Extra Items

4,700

-115

985

642

1,570

1,828

Total Shares Outstanding

1,394.9

1,416.6

1,425.5

1,433.3

1,465.7

1,470.6

Weighted Avg. Shares Outstanding

1,391.5

1,416.7

1,422.3

1,430.5

1,453

1,467.3

Weighted Avg. Shares Outstanding Dil

1,410.6

1,416.7

1,433.8

1,439.7

1,463.5

1,479.5

EPS

3.4

-0.1

0.7

0.4

1.1

1.2

EPS Diluted

3.3

-0.1

0.7

0.4

1.1

1.2

EBITDA

2,842

2,075

2,917

3,169

3,613

3,956

Effective Tax Rate

-584.1%

-2.5%

3.3%

38.8%

19.8%

14.9%